BIOGEN INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224.3 USD | +1.25% |
|
-2.22% | -13.44% |
| 05:28pm | Biogen Needs Revenue-Generating Assets to Complete Turnaround, Wedbush Says | MT |
| 03:00pm | Redburn Atlantic Adjusts Price Target on Biogen to $230 From $235, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
221.6
USD
Average target price
281.1
USD
Spread / Average Target
+26.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.44% | 32.26B | |
| +7.40% | 101B | |
| +8.42% | 42.18B | |
| +80.80% | 29.79B | |
| -11.74% | 16.06B | |
| +1.82% | 14.45B | |
| -6.77% | 12.01B | |
| +177.16% | 10.71B | |
| +4.12% | 8.89B | |
| -56.13% | 8.83B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen Needs Revenue-Generating Assets to Complete Turnaround, Wedbush Says
